Back to Agenda
Session 4 / Venue 4: Issues to be Addressed from the Result of Metrics Analyses - Maximizing Japan's Strength
Session Chair(s)
Takuya Oshida, PharmD, MSc
Senior Vice President, Head of Medical Affairs, Japan, Medical Affairs Japan
Astellas Pharma Inc., Japan
Recent years have seen improvements in the environments and performance of domestic clinical trials to a level competitive with those overseas thanks to the efforts by pharmaceutical companies, regulatory agencies, medical institutions, etc. To demonstrate the presence of Japan in the global development of drugs, however, we need to address various issues yet to be solved while leveraging our strength of operational excellence. In this session, we intend to explore which issues are further to be addressed for future clinical trials in this country, under the constantly changing environment.
Speaker(s)
The Transition of Clinical Trials Environment in Japan
Toko Shimomukai
Japan Tobacco Inc., Japan
JPMA, Clinical Evaluation Expert Committee, Drug Evaluation Committee
Performance Analysis of Local Clinical Trials Using Metrics from Viewpoint of Japanese Pharmaceutical Company
Yuji Kawamura
Astellas Pharma Inc., Japan
The Performance of Domestic Clinical Trials Conduction from the Global CRO Point of View
Koji Ando
Quintiles Transnational Japan K.K., Japan
Director
Have an account?